A phase 3 trial presented at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago shows that a daily oral drug, daraxonrasib, roughly doubled median survival for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC). The randomized study enrolled about 500 patients whose cancer had already spread; those taking daraxonrasib survived a median 13.2 months versus 6.6–6.7 months for patients receiving standard chemotherapy. Investigators reported fewer and milder side effects than with conventional regimens. Experts at the meeting called the data a potential turning point for a disease long resistant to effective systemic treatments.
Key takeaways
- Trial size and setting: Approximately 500 patients with metastatic pancreatic cancer were enrolled and results were presented at ASCO in Chicago.
- Survival benefit: Median overall survival was 13.2 months for daraxonrasib-treated patients versus 6.6–6.7 months for the chemotherapy control arm.
- Safety profile: Investigators reported fewer adverse events and a more favorable tolerability profile compared with standard chemotherapy.
- Mechanism: Daraxonrasib targets the KRAS protein, a driver in >90% of pancreatic ductal adenocarcinoma cases, using a multi-selective Ras(On) inhibitory approach.
- Leadership and provenance: The trial was led by researchers at Dana-Farber Cancer Institute and disclosed at ASCO’s annual meeting.
- Clinical significance: Specialists described the results as “landscape-changing” and likened the impact to a major breakthrough for a cancer with historically dismal outcomes.
- Broader potential: Because KRAS mutations fuel other malignancies, similar agents are already in trials for lung and colorectal cancers.
Background
Pancreatic cancer is among the deadliest common cancers: most cases are detected at an advanced stage and five-year survival rates have remained low despite decades of research. Pancreatic ductal adenocarcinoma (mPDAC) is the predominant subtype; more than half of patients are diagnosed only after the tumour has metastasized, limiting curative options. Historically, systemic treatments have offered only modest benefits in advanced disease, and new therapeutic classes have been rare.
A major reason for the therapeutic gap has been the central role of KRAS mutations in driving pancreatic cancer growth. KRAS (part of the Ras gene family) can lock signalling pathways in an active state, pushing cells to proliferate and resist death. For years, the KRAS protein was deemed an exceptionally difficult drug target, and multiple attempts to inhibit it clinically failed or produced limited results. The new class of Ras(On) multi-selective inhibitors represents a deliberate effort to overcome those biochemical obstacles.
Main event
The randomized phase 3 trial enrolled roughly 500 patients with metastatic pancreatic cancer and compared daily oral daraxonrasib to standard chemotherapy regimens. Investigators reported a median overall survival of 13.2 months in the daraxonrasib arm versus 6.6–6.7 months for patients on chemotherapy, effectively about a twofold increase in median survival time. The results were unveiled at ASCO’s annual meeting in Chicago, where clinicians and researchers examined detailed efficacy and safety data.
According to the presenters, daraxonrasib acts by binding and stabilizing complexes that inactivate the KRAS protein, blocking the signalling cascade that fuels tumour growth. The effect was observed across patients regardless of the specific KRAS variant, a notable point because different Ras mutations have previously posed distinct therapeutic challenges. Trial investigators emphasized that the drug produced a meaningful survival gain while causing fewer severe toxicities than typical chemotherapy.
Study authors and external experts highlighted the emotional and clinical weight of the findings. Dr Rachna Shroff, oncology chief at the University of Arizona Cancer Center and an ASCO gastrointestinal cancers expert not involved in the trial, described the results as unprecedented in her clinical experience. ASCO’s Dr Julie Gralow called the outcome a “gamechanger,” framing the trial as a major advance for a cancer type long resistant to transformative therapies.
Analysis & implications
If regulatory agencies confirm the trial’s findings and approve daraxonrasib, the drug could rapidly alter the standard of care for metastatic pancreatic cancer, shifting practice away from purely cytotoxic chemotherapy toward targeted oral therapy. The magnitude of the median survival improvement—roughly doubling—would be unusually large for a single-agent intervention in this disease, which raises hopes for meaningful clinical benefit in routine care. However, regulatory review, additional confirmatory datasets, and post-marketing safety surveillance will be essential steps before widespread adoption.
Practical challenges remain: access to the drug, pricing and reimbursement negotiations, and diagnostic pathways to identify patients most likely to benefit. Although the trial reported benefit irrespective of KRAS variant, routine molecular testing will probably expand to guide use and to monitor for resistance mechanisms that could emerge with broader exposure. Health systems will need to prepare for test-and-treat pathways and potential demand for a new targeted oral therapy at scale.
The implications extend beyond pancreas cancer. KRAS mutations occur in other common tumours, including certain lung and colorectal cancers; investigators and industry are already testing similar agents in those indications. If daraxonrasib’s mechanism proves robust, it could catalyze a broader Ras-targeted drug class and encourage combination studies with immunotherapy, cytotoxics or other targeted agents to deepen and prolong responses.
Comparison & data
| Group | Median overall survival (months) | Relative tolerability |
|---|---|---|
| Daraxonrasib (oral) | 13.2 | Fewer severe adverse events reported |
| Standard chemotherapy | 6.6–6.7 | Higher rates of chemotherapy-related toxicity |
The table highlights the principal numerical result disclosed by the study: a median survival of 13.2 months with daraxonrasib versus about 6.6–6.7 months with chemotherapy. The trial also reported an improved tolerability profile for the oral agent, which could translate into better quality of life during treatment. Further data on response rates, progression-free survival, and subgroup analyses will be necessary to understand which patients gain the greatest absolute benefit.
Reactions & quotes
Clinicians and patient advocates at ASCO reacted with a mix of professional excitement and emotional relief given decades of limited progress in pancreatic cancer therapy.
“These results are landscape-changing.”
Dr Rachna Shroff, University of Arizona Cancer Center (ASCO expert, not part of the trial)
Shroff’s comment followed a description of how rare such a substantial median survival gain is in metastatic pancreatic cancer; she emphasized the practical meaning for patients and clinicians. Her reaction underlined the emotional resonance of the data after many years of marginal advances.
“I’ve heard this study described as a home run. I would actually say it’s a grand slam.”
Dr Julie Gralow, ASCO Chief Medical Officer (not part of the trial)
Dr Gralow framed the trial as a potential paradigm shift for care standards, while patient group leaders stressed the need to translate the scientific advance into rapid and equitable patient access.
Unconfirmed
- Long-term outcomes beyond median survival remain to be reported; data on two- and three-year survival rates are not yet available.
- Real-world effectiveness and safety outside the controlled trial setting have not been established and may differ from trial results.
- The timeline for regulatory approval, reimbursement decisions and global availability is unresolved and will vary by jurisdiction.
- Whether daraxonrasib will be effective in earlier-stage pancreatic cancer or as adjuvant therapy has not been tested in this trial.
Bottom line
The phase 3 findings for daraxonrasib represent one of the most substantial single-agent advances reported in metastatic pancreatic cancer in decades, with a median survival increase from about 6.6–6.7 months to 13.2 months and a favourable tolerability signal. If subsequent regulatory review, peer-reviewed publication and real-world experience confirm these outcomes, clinical practice could pivot toward routine use of KRAS-targeting oral therapy for many patients with advanced disease.
Key next steps include regulatory assessment, publication of full trial data (including subgroup and safety breakdowns), expansion of molecular testing infrastructure, and planning for equitable access. For patients and families, the result offers meaningful extra months and renewed momentum for research into Ras-targeted strategies across multiple cancers.